Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Predictive Markers of Oxaliplatin Neurotoxicity in Colorectal Cancer
NCT00884767Phase 2Unknown
- Sponsor
- Institut Cancérologique de l'Ouest
- Start
- Sep 2007
- Primary completion
- Aug 2009
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin in colorectal cancer (CRC), sponsored by Institut Cancérologique de l'Ouest. Primary endpoint: Correlation of genetic profiles and peptide, protein, and neurotrophic factors with neurological toxicity. Status: unknown.
02
Drugs
oxaliplatin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00884767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00884767.